Sep. 14 at 4:21 PM
$XLO Xilio expects to receive payment of the
$17.5 million development milestone by the fourth quarter of 2025.
$ALZN The first of five clinical trials began in May 2025 with healthy volunteers, which will assess AL001’s brain/plasma pharmacokinetics, safety, and distribution compared to lithium carbonate. Topline results are expected by year-end 2025
We intend to initiate four more identical clinical trials, with the first of these trials, for treatment of patients with BD, expected to commence in the third quarter of 2025
$LAES reported progress across multiple initiatives, including the QUASAR Program, where engineering samples of its QS7001™ post-quantum microcontroller were delivered to partners in Q2 2025 with production samples and development kits expected by the end of Q3 2025. The Company also plans to begin pilot-customer sampling of its QVault TPM V183 in Q4 2025. In addition, SEALSQ highlighted its participation in the €40 million Quantix Edge Security Joint Venture launched by the Government of Spain, to which SEALSQ and its parent WISeKey will contribute approximately 25%, with the establishment of the Spanish entity anticipated in early Q4
